HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles


Cleveland BioLabsCleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. CBLI’s programs are focused on the use of novel toll-like receptor agonists to activate the immune system for therapeutic benefit. The Company's most advanced product candidate is entolimod, which is being developed as a radiation countermeasure and an immunotherapy for oncology and other indications. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute.

CBLI is focused on achieving two major objectives:

  1. Commercializing entolimod as a medical radiation countermeasure through pre-Emergency Use Authorization.
  2. Achieving clinical validation and partnerships for cancer immunotherapies and vaccine adjuvant technology.
Yahoo Data and NewsCompany Web Site

Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

Code Rebel Completes Initial Public Offering and Begins Trading on NASDAQ Capital Market

HONOLULU, HI and NEW YORK, NY– May 19, 2015 – Code Rebel Corp. (NASDAQ: CDRB), an enterprise software company focused on developing innovative technologies to simplify access and communication with and between virtually any computer, tablet or smartphone, announced today that it has completed its initial public offering of shares of common stock. The shares of common stock will begin trading today, May 19, 2015, on the NASDAQ Capital Market. 

(full story)

Cleveland BioLabs Appoints Langdon Miller, MD, as President

BUFFALO, NY-- May 5, 2015 - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Langdon L. Miller, M.D., as President and Chief Medical Officer, effective immediately.

(full story)

Corbus Pharmaceuticals Announces Uplisting to the NASDAQ Capital Market

NORWOOD, MA -- Apr 13, 2015 - Corbus Pharmaceuticals Holdings, Inc. (CRBP) (the Company), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab, ™ for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that the NASDAQ Stock Market LLC has approved the Company's application to have its common stock listed on The NASDAQ Capital Market (NASDAQ). The stock will commence trading on The NASDAQ Capital Market on April 16, 2015, under its existing ticker symbol CRBP.


(full story)

More Articles

Upcoming Events

There are no events to display at this time.
Complete Events List

Code RebelCode Rebel
Code Rebel is an enterprise software company that develops, licenses and supports computer software designed for employee productivity and enterprise security across multiple platforms. The proprietary Code Rebel iRAPP software seeks to address the growing requirement of corporate IT departments to provide secure employee access from all their devices to all their devices and to other corporate resources. Code Rebel was co-founded by its computer engineering team to address the demand in the marketplace for secure interoperability between mobile, desktop and server environments with seamless interaction between Apple and Microsoft devices and software. The company supports its enterprise licensees from diverse industries, including banking, healthcare, retail, pharmaceutical, education and telecommunications.
Yahoo Data and NewsCompany Web Site

CorbusCorbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs. The Company’s lead product Resunab is a first- in-class oral anti-inflammatory expected to commence Phase-2a clinical trials for the treatment of cystic fibrosis and scleroderma pending FDA approval of IND.

About Resunab™
Resunab is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have an excellent safety profile in humans and promising potency. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution", in effect turning chronic inflammation "off."
Yahoo Data and NewsCompany Web Site






  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved